Linked Life Data

6893952

Source:http://linkedlifedata.com/resource/pubmed/id/6893952

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10-11
pubmed:dateCreated
1981-4-13
pubmed:abstractText
A disease-oriented trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide) given once every 3 weeks was undertaken in patients with advanced non-Hodgkin's lymphoma. None of 15 adequately treated patients achieved complete or partial remissions. Toxicity was mild-to-moderate, consisting of myelosuppression (principally granulocytopenia) and malaise. The lack of any major responses in this number of patients suggests that, in this schedule, the drug is not useful in therapy for advanced non-Hodgkin's lymphoma.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0361-5960
pubmed:author
pubmed:issnType
Print
pubmed:volume
64
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1157-8
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:articleTitle
Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.